The most widely applied technology for G6PD screening—the fluorescent spot test (FST)—is impractical in that setting.
One of the most widely recommended and used has been the fluorescent spot test (FST) described in 1966 by hematologist and pioneering G6PD scientist Ernest Beutler.
It has seen several decades of practical and safe use in the developed world, but finds almost no routine application where most patients with malaria live.
In impoverished rural settings, patients very often are not provided primaquine therapy as a direct consequence of a lack of access to G6PD screening.
G6PD deficiency as the basis of hemolytic sensitivity to primaquine was described in 1956, and a variety of diagnostic tests for the disorder appeared within a decade.